Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Cancer
Metastatic Head and Neck Squamous Cell Cancer

Interventions: Drug: Cabozantinib
Drug: Cetuximab

First Posted Date: 2018-09-12

Last Posted Date: 2024-07-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT03667482

Locations: 🇺🇸
Baptist Alliance MCI, Miami, Florida, United States
🇺🇸
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 6 locations

Investigating the Impact of Proactive Palliative Care

Active, not recruiting

Conditions: Locally Advanced Solid Tumor Cancers
Metastatic Solid Tumor Cancers

Interventions: Behavioral: Expectations Survey (CanCORS)
Behavioral: Values Survey (Serious Illness Care Program)
Behavioral: Functional Assessment of Cancer Therapy-General (FACT-G)
Behavioral: NCCN Distress Thermometer
Behavioral: Hospital Anxiety and Depression Scale (HADS)
Behavioral: Quality of Communication (QOC)
Behavioral: visits with a supportive care clinician

First Posted Date: 2018-09-12

Last Posted Date: 2024-10-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 83

Registration Number: NCT03667378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: 89Zr-daratumumab
Device: PET/CT scans
Other: Blood draws

First Posted Date: 2018-09-11

Last Posted Date: 2021-07-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT03665155

Locations: 🇺🇸
Memorial Slaon-Kettering Cancer Center, New York, New York, United States

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

Conditions: Survivors of Unilateral Retinoblastoma

Interventions: Behavioral: BASC-3 survey
Behavioral: PROMIS survey

First Posted Date: 2018-09-07

Last Posted Date: 2023-09-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 120

Registration Number: NCT03662776

Locations: 🇺🇸
Texas Children's Hospital (Data Collection), Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Phase 1

Recruiting

Conditions: Thyroid Carcinoma
Metastatic Thyroid Carcinoma

Interventions: Device: PET/CT Scan
Drug: Iodine-124

First Posted Date: 2018-08-27

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT03647358

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Adenocarcinoma of Endometrium

Interventions: Drug: Fulvestrant
Drug: Abemaciclib

First Posted Date: 2018-08-22

Last Posted Date: 2024-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT03643510

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
Unclassified Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Collecting Duct Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma

Interventions: Drug: cabozantinib
Drug: nivolumab

First Posted Date: 2018-08-17

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT03635892

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Phase 1

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: [18F]- PARPi
Diagnostic Test: PET/CT Scans

First Posted Date: 2018-08-15

Last Posted Date: 2024-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT03631017

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Phase 2

Active, not recruiting

Conditions: AL Amyloidosis

Interventions: Drug: Ixazomib
Drug: Dexamethasone

First Posted Date: 2018-08-07

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03618537

Locations: 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma

Interventions: Drug: pembrolizumab
Drug: gemcitabine
Drug: vinorelbine
Drug: liposomal doxorubicin
Procedure: Stem cell mobilization and collection

First Posted Date: 2018-08-07

Last Posted Date: 2024-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 257

Registration Number: NCT03618550

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy